Search

Your search keyword '"Guerra, Eva M."' showing total 15 results
Start Over Author "Guerra, Eva M."
15 results on '"Guerra, Eva M."'

2. Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer

Author

Makker, Vicky, Colombo, Nicoletta, Herráez, Antonio Casado, Santin, Alessandro D., Colomba, Emeline, Miller, David S., Fujiwara, Keiichi, Pignata, Sandro, Baron-Hay, Sally, Ray-Coquard, Isabelle, Shapira-Frommer, Ronnie, Ushijima, Kimio, Sakata, Jun, Yonemori, Kan, Kim, Yong Man, Guerra, Eva M., Sanli, Ulus A., McCormack, Mary M., Smith, Alan D., Keefe, Stephen, Bird, Steven, Dutta, Lea, Orlowski, Robert J., and Lorusso, Domenica

Published
2022
Full Text
View/download PDF

3. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

Author

Mirza, Mansoor R, primary, González-Martín, Antonio, additional, Graybill, Whitney S, additional, O'Malley, David M, additional, Gaba, Lydia, additional, Stephanie Yap, Oi Wah, additional, Guerra, Eva M, additional, Rose, Peter G, additional, Baurain, Jean-François, additional, Ghamande, Sharad A, additional, Denys, Hannelore, additional, Prendergast, Emily, additional, Pisano, Carmela, additional, Follana, Philippe, additional, Baumann, Klaus, additional, Calvert, Paula M, additional, Korach, Jacob, additional, Li, Yong, additional, Malinowska, Izabela A, additional, Gupta, Divya, additional, and Monk, Bradley J, additional

Published
2024
Full Text
View/download PDF

4. Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT‐OV26/GOG‐3012 trial

Author

Mirza, Mansoor R., primary, González‐Martín, Antonio, additional, Graybill, Whitney S., additional, O’Malley, David M., additional, Gaba, Lydia, additional, Stephanie Yap, Oi Wah, additional, Guerra, Eva M., additional, Rose, Peter G., additional, Baurain, Jean‐François, additional, Ghamande, Sharad A., additional, Denys, Hannelore, additional, Prendergast, Emily, additional, Pisano, Carmela, additional, Follana, Philippe, additional, Baumann, Klaus, additional, Calvert, Paula M., additional, Korach, Jacob, additional, Li, Yong, additional, Malinowska, Izabela A., additional, Gupta, Divya, additional, and Monk, Bradley J., additional

Published
2023
Full Text
View/download PDF

5. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.

Author

Vergote, Ignace, Pérez-Fidalgo, Jose Alejandro, Hamilton, Erika Paige, Valabrega, Giorgio, Van Gorp, Toon, Sehouli, Jalid, Cibula, David, Levy, Tally, Welch, Stephen, Richardson, Debra L., Guerra, Eva M., Scambia, Giovanni, Henry, Stéphanie, Wimberger, Pauline, Miller, David S., Klat, Jaroslav, Martínez-Garcia, Jerónimo, Raspagliesi, Francesco, Pothuri, Bhavana, and Romero, Ignacio

Published
2023
Full Text
View/download PDF

6. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

Author

Makker, V, Colombo, N, Casado Herráez, A, Santin, A, Colomba, E, Miller, D, Fujiwara, K, Pignata, S, Baron-Hay, S, Ray-Coquard, I, Shapira-Frommer, R, Ushijima, K, Sakata, J, Yonemori, K, Kim, Y, Guerra, E, Sanli, U, Mccormack, M, Smith, A, Keefe, S, Bird, S, Dutta, L, Orlowski, R, Lorusso, D, Makker, Vicky, Colombo, Nicoletta, Casado Herráez, Antonio, Santin, Alessandro D, Colomba, Emeline, Miller, David S, Fujiwara, Keiichi, Pignata, Sandro, Baron-Hay, Sally, Ray-Coquard, Isabelle, Shapira-Frommer, Ronnie, Ushijima, Kimio, Sakata, Jun, Yonemori, Kan, Kim, Yong Man, Guerra, Eva M, Sanli, Ulus A, McCormack, Mary M, Smith, Alan D, Keefe, Stephen, Bird, Steven, Dutta, Lea, Orlowski, Robert J, Lorusso, Domenica, Makker, V, Colombo, N, Casado Herráez, A, Santin, A, Colomba, E, Miller, D, Fujiwara, K, Pignata, S, Baron-Hay, S, Ray-Coquard, I, Shapira-Frommer, R, Ushijima, K, Sakata, J, Yonemori, K, Kim, Y, Guerra, E, Sanli, U, Mccormack, M, Smith, A, Keefe, S, Bird, S, Dutta, L, Orlowski, R, Lorusso, D, Makker, Vicky, Colombo, Nicoletta, Casado Herráez, Antonio, Santin, Alessandro D, Colomba, Emeline, Miller, David S, Fujiwara, Keiichi, Pignata, Sandro, Baron-Hay, Sally, Ray-Coquard, Isabelle, Shapira-Frommer, Ronnie, Ushijima, Kimio, Sakata, Jun, Yonemori, Kan, Kim, Yong Man, Guerra, Eva M, Sanli, Ulus A, McCormack, Mary M, Smith, Alan D, Keefe, Stephen, Bird, Steven, Dutta, Lea, Orlowski, Robert J, and Lorusso, Domenica

Abstract

BACKGROUND Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear. METHODS In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previously received at least one platinum-based chemotherapy regimen to receive either lenvatinib (20 mg, administered orally once daily) plus pembrolizumab (200 mg, administered intravenously every 3 weeks) or chemotherapy of the treating physician’s choice (doxorubicin at 60 mg per square meter of body-surface area, administered intravenously every 3 weeks, or paclitaxel at 80 mg per square meter, administered intravenously weekly [with a cycle of 3 weeks on and 1 week off]). The two primary end points were progression-free survival as assessed on blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1, and overall survival. The end points were evaluated in patients with mismatch repair–proficient (pMMR) disease and in all patients. Safety was also assessed. RESULTS A total of 827 patients (697 with pMMR disease and 130 with mismatch repair–deficient disease) were randomly assigned to receive lenvatinib plus pembrolizumab (411 patients) or chemotherapy (416 patients). The median progression-free survival was longer with lenvatinib plus pembrolizumab than with chemotherapy (pMMR population: 6.6 vs. 3.8 months; hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.50 to 0.72; P<0.001; overall: 7.2 vs. 3.8 months; hazard ratio, 0.56; 95% CI, 0.47 to 0.66; P<0.001). The median overall survival was longer with lenvatinib plus pembrolizumab than with chemotherapy (pMMR population: 17.4 vs. 12.0 months; hazard ratio for death, 0.68; 95% CI, 0.56 to 0.84; P<0.001; overall: 18.3 vs. 11.4 months; hazard ratio, 0.62; 95% CI, 0.51 to 0.75; P<0.001). Adverse events of grade 3 or higher occurred in 88.9% of the patients who received lenvatinib plus pembr

Published
2022

7. Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775.

Author

Makker, Vicky, primary, Colombo, Nicoletta, additional, Santin, Alessandro, additional, Miller, David Scott, additional, Fujiwara, Keiichi, additional, Pignata, Sandro, additional, Ray-Coquard, Isabelle Laure, additional, Kim, Yong Man, additional, Guerra, Eva M., additional, Huang, Jie, additional, Barresi, Gianmaria, additional, McKenzie, Jodi, additional, and Lorusso, Domenica, additional

Published
2022
Full Text
View/download PDF

8. Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification.

Author

Makker, Vicky, primary, Perez-Fidalgo, Jose Alejandro, additional, Bergamini, Alice, additional, Spitz, Daniel Lewis, additional, Van Gorp, Toon, additional, Sehouli, Jalid, additional, Klat, Jaroslav, additional, Perri, Tamar, additional, Oza, Amit M., additional, Hogdall, Estrid Vilma Solyom, additional, Konner, Jason A., additional, Guerra, Eva M., additional, Raspagliesi, Francesco, additional, Henry, Stephanie, additional, Monk, Bradley J., additional, Martinez Garcia, Jeronimo, additional, Slomovitz, Brian M., additional, Shacham, Sharon, additional, Mirza, Mansoor Raza, additional, and Vergote, Ignace, additional

Published
2022
Full Text
View/download PDF

9. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

Author

Makker, Vicky, primary, Colombo, Nicoletta, additional, Casado Herráez, Antonio, additional, Santin, Alessandro D., additional, Colomba, Emeline, additional, Miller, David S., additional, Fujiwara, Keiichi, additional, Pignata, Sandro, additional, Baron-Hay, Sally, additional, Ray-Coquard, Isabelle, additional, Shapira-Frommer, Ronnie, additional, Ushijima, Kimio, additional, Sakata, Jun, additional, Yonemori, Kan, additional, Kim, Yong Man, additional, Guerra, Eva M., additional, Sanli, Ulus A., additional, McCormack, Mary M., additional, Smith, Alan D., additional, Keefe, Stephen, additional, Bird, Steven, additional, Dutta, Lea, additional, Orlowski, Robert J., additional, and Lorusso, Domenica, additional

Published
2022
Full Text
View/download PDF

10. Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.

Author

Italiano, Antoine, primary, Verlingue, Loic, additional, Prenen, Hans, additional, Guerra, Eva M., additional, Tosi, Diego, additional, Perets, Ruth, additional, Lugowska, Iwona, additional, Moiseenko, Vladimir, additional, Gumus, Mahmut, additional, Arslan, Cagatay, additional, Lindsay, Colin R., additional, Richard, Muriel, additional, Dejardin, David, additional, Boetsch, Christophe, additional, Kraxner, Anton, additional, Evers, Stefan, additional, Vardar, Taner, additional, Keshelava, Nino, additional, Teichgräber, Volker, additional, and Dziadziuszko, Rafal, additional

Published
2021
Full Text
View/download PDF

11. SIENDO/ENGOT-EN5: A randomized phase III trial of maintenance with selinexor/placebo after combination chemotherapy in patients with advanced or recurrent endometrial cancer.

Author

Vergote, Ignace, primary, Hamilton, Erika Paige, additional, Romero, Ignacio, additional, Guerra, Eva M., additional, Buscema, Joseph, additional, Laenen, Annouschka, additional, Perri, Tamar, additional, Estévez-García, Purificación, additional, Gomez Raposo, Cesar, additional, Levy, Tally, additional, Valabrega, Giorgio, additional, Martinez Garcia, Jeronimo, additional, Mangili, Giorgia, additional, Makker, Vicky, additional, Michel, Dayana, additional, Wang, Hongwei, additional, and Mirza, Mansoor Raza, additional

Published
2020
Full Text
View/download PDF

12. Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.

Author

Mirza, Mansoor Raza, primary, Gonzalez Martin, Antonio, additional, Graybill, Whitney, additional, O'Malley, David M., additional, Gaba, Lydia, additional, Yap, Oi Wah S., additional, Guerra, Eva M., additional, Rose, Peter Graham, additional, Baurain, Jean-Francois, additional, Ghamande, Sharad A., additional, denys, Hannelore, additional, Prendergast, Emily, additional, Pisano, Carmela, additional, Follana, Philippe, additional, Baumann, Klaus, additional, Calvert, Paula, additional, Korach, Jacob, additional, Li, Yong, additional, Gupta, Divya, additional, and Monk, Bradley J., additional

Published
2020
Full Text
View/download PDF

13. Randomized phase II study of sapanisertib (SAP) + paclitaxel (PAC) versus PAC alone in patients (pts) with advanced, recurrent, or persistent endometrial cancer.

Author

Scambia, Giovanni, primary, Han, Sileny N., additional, Oza, Amit M., additional, Colombo, Nicoletta, additional, Oaknin, Ana, additional, Raspagliesi, Francesco, additional, Wenham, Robert Michael, additional, Braicu, Elena Ioana, additional, Jewell, Andrea, additional, Makker, Vicky, additional, Guerra, Eva M., additional, Moxley, Katherine M., additional, Baurain, Jean-Francois, additional, Su, Zhenqiang, additional, Neuwirth, Rachel, additional, Vincent, Sylvie, additional, Sedarati, Farhad, additional, Faller, Douglas V., additional, and Krell, Jonathan, additional

Published
2020
Full Text
View/download PDF

14. Association of anthracyclines induced cardiotoxicity (AIC) in patients with early breast cancer (eBC) with germline BRCA1/2 (gBRCA1/2) mutation: BRCAN study.

Author

Serrano Domingo, Juan José, Cordero, David, Menacho, Miriam, del Rey, Jose Manuel, Chamorro, Jesús, Rosero, Diana I., Sotoca, Pilar, del Campo, Laura, Alonso, Gonzalo, Saavedra Serrano, Cristina, Fernández-Abad, María, Gion Cortes, Maria, Guerra, Eva M., Martinez-Jañez, Noelia, Lopez-Miranda, Elena, Vida Navas, Elena Maria, Fuentes Mateos, Raquel, GUILLEN PONCE, CARMEN, Salazar, Maria Teresa, and Cortés Salgado, Alfonso

Published
2023
Full Text
View/download PDF

15. Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.

Author

Harter, Philipp, Mouret-Reynier, Marie-Ange, Lorusso, Domenica, Cropet, Claire, Guerra, Eva M., Wolfrum-Ristau, Pia, Matsumoto, Takashi, Vergote, Ignace, Colombo, Nicoletta, Maenpaa, Johanna Unelma, Lebreton, Coriolan, de Gregorio, Nikolaus, Mosconi, Anna Maria, Rubio-Pérez, Maria Jesús, Bourgeois, Hugues, Fasching, Peter A., Hardy-Bessard, Anne-Claire, Denschlag, Dominik, Pujade-Lauraine, Eric, and Ray-Coquard, Isabelle Laure

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results